KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi K, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S.

    Efficacy and safety of romiplostim refractory aplastic anemia: a phase 2/3, multicentre, open-label study.

    Brit J Haematol 192(1):190-199,2021. doi: 10.1111/bjh.17190. Epub 2020 Nov 5.

    https://pubmed.ncbi.nlm.nih.gov/33152120/

     

  2. Ishihara A, Yamauchi T, Ikeda K, Fukuyoshi Y, Yokoyama T, Yonemura Y, Uchiba M, Matsui H.

    Glycosylated ferritin as an improved marker for post-transfusion iron overload.

    Int J Hematol 113(4): 537-546,2021. doi: 10.1007/s12185-020-03056-9. Epub 2021 Jan 5.

    https://pubmed.ncbi.nlm.nih.gov/33400141/

     

  3. Guangyong Ma, Jun-ichirou Yasunaga, Kazuya Shimurab, Keiko Takemotob, Miho Watanabec, Masayuki Amano, Hirotomo Nakata, Benquan Liua, Xiaorui Zuoa, and Masao Matsuoka

    Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence

    Proc Natl Acad Sci U S A.2021 Apr 27;118(17):e2014783118. doi: 10.1073/pnas.2014783118.

    https://pubmed.ncbi.nlm.nih.gov/33875584/

     

     

  4. Sakata K, Kikuchi J, Emoto K, Kotaki T, Ota Y, Nishina N, Hanaoka H, Otomo K, Suzuki K, Kaneko Y, Takeuchi T.

    Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review.

    Intern Med 60(13):2135-2143,2021.doi: 10.2169/internalmedicine.6313-20. Epub 2021 Feb 1.

    https://pubmed.ncbi.nlm.nih.gov/33518567/

     

  5. Penova M, Kawaguchi S, Yasunaga JI, Kawaguchi T, Sato T, Takahashi M, Shimizu M, Saito M, Tsukasaki K, Nakagawa M, Takenouchi N, Hara H, Matsuura E, Nozuma S, Takashima H, Izumo S, Watanabe T, Uchimaru K, Iwanaga M, Utsunomiya A, Tabara Y, Paul R, Yamano Y, Matsuoka M and Matsuda F.

    HTLV-1 associated myelopathy/tropical spastic paraparesis in the Japanese population – a genome-wide association study.

     Proc Natl Acad Sci USA 118(11):e2004199118. doi: 10.1073/pnas.2004199118.

    https://pubmed.ncbi.nlm.nih.gov/33649182/

     

  6. Nosaka K and Matsuoka M

    Adult T-cell leukemia-lymphoma as a viral disease: subtypes based on viral aspects.

    ancer Sci ,112(5):1688-1694. doi: 10.1111/cas.14869. Epub 2021 Mar 30.

    https://pubmed.ncbi.nlm.nih.gov/33630351/

     

     

  7. Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M and Zhao T

    The noncanonical role of EZH2 in cancer.

    Cancer Sci 112(4):1376-1382. doi: 10.1111/cas.14840. Epub 2021 Feb 24.

    https://pubmed.ncbi.nlm.nih.gov/33615636/

     

  8. Travis Chia, Tomofumi Nakamura, Masayuki Amano, Nobutoki Takamune, Masao Matsuoka, Hirotomo Nakata

    A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid

    Antimicrob Agents Chemother. 2021 Jul 6;AAC0103921. doi: 10.1128/AAC.01039-21. Online ahead of print.

    https://pubmed.ncbi.nlm.nih.gov/34228546/

     

  9. Izaki M, Yasunaga JI, Nosaka K, Sugata K, Utsunomiya H, Suehiro Y, Shichijo T, Yamada A, Sugawara Y, Hibi T, Inomata Y, Akari H, Melamed A, Bangham C, Matsuoka M.

    In vivo dynamics and adaptation of HTV-1-infected clones under different clinical conditions

    PLOS Pathogens.2021 Feb 1;17(2):e1009271. doi: 10.1371/journal.ppat.1009271. Online ahead of print .PMID: 33524072

    https://pubmed.ncbi.nlm.nih.gov/33524072/

     

  10. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K and Tobinai K.

    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

    Eur J Haematol 106(2): 213-220. doi: 10.1111/ejh.13539. Epub 2020 Nov 6.

    https://pubmed.ncbi.nlm.nih.gov/33098704/

     

     

  11. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K and Tobinai K.

    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

    Eur J Haematol 106(2): 213-220,2021. doi: 10.1111/ejh.13539. Epub 2020 Nov 6.

    https://pubmed.ncbi.nlm.nih.gov/33098704/

     

  12. Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Seki M, Tanabe Y, Fujita N, Niki Y, Morita K, Yanagihara K, Yoshida K, Kawaguchi T.

    Impact of health policy on structural requisites for antimicrobial stewardship: A nationwide survey conducted in Japanese hospitals after enforcing the revised reimbursement system for antimicrobial stewardship programs.

    J Infect Chemother 27(1):1-6,2021. doi: 10.1016/j.jiac.2020.09.015.

    https://pubmed.ncbi.nlm.nih.gov/33008739/

     

  13. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiyo Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H Japan Clinical Oncology Group.

    A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

    Blood Adv 5(4):984-993,2021. doi: 10.1182/bloodadvances.2020002567.

    https://pubmed.ncbi.nlm.nih.gov/33591324/

     

  14. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S.

    Prophylactic antiviral therapy for HBsAg-positive patients with DLBCL treated with rituximab-containing chemotherapy.

    Cancer Sci 112(5):1943-1954,2021. doi: 10.1111/cas.14846. Epub 2021 Mar 18.

    https://pubmed.ncbi.nlm.nih.gov/33576088/

     

  15. Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gulla A, Samur AA, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Via MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM, Anderson KC.

    ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

    Blood Cancer Discovery 2(4):338-353.2021. doi: 10.1158/2643-3230.BCD-20-0164. Epub 2021 Apr 10.

    https://pubmed.ncbi.nlm.nih.gov/34238761/

     

  16. Shen YJ, Mishima Y, Shi J, Pistofidis RS, Redd R, Moschetta M, Manier S, Roccaro A, Sacco A, Tai YT, Mercier F, Kawano Y, Su N, Berrios B, Doench J, Root D, Michor F, Scadden D, Ghobrial IM.

    Progression signature underlies clonal evolution and dissemination of multiple myeloma.

    Blood 137(17):2360-2372,2021. doi: 10.1182/blood.2020005885.

    https://pubmed.ncbi.nlm.nih.gov/33150374/

     

     

  17. Ishihara A, Yamauchi T, Ikeda K, Fukuyoshi Y, Yokoyama T, Yonemura Y, Uchiba M, Matsui H

    Glycosylated ferritin as an improved marker for post-transfusion iron overload.

    Int J Hematol 113(4): 537-546,2021.  doi: 10.1007/s12185-020-03056-9. Epub 2021 Jan 5.

    https://pubmed.ncbi.nlm.nih.gov/33400141/

     

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.